IntelGenx announces co-development, commercialization of VersaFilm products

IntelGenx (IGXT) announced that it and Tilray Brands (TLRY) have entered into a further amendment to their November 2018 license, development and supply agreement for the co-development and commercialization of cannabinoid-infused VersaFilm products, settling IntelGenx’s arbitration claim against Tilray. Pursuant to the Second Amendment, IntelGenx has received an initial purchase order from Tilray for three SKUs, with each SKU totalling 130,000 filmstrips. The Second Amendment also allows for IntelGenx’s co-development and commercialization of CBD, THC, and combination THC:CBD products with additional partners. The Second Agreement removes any royalties paid to or from Tilray. “This partnership and settlement represent a significant milestone in building our relations with Tilray, and we are excited to begin this new chapter of the companies making innovative cannabinoid-infused oral thin film products available to consumers,” said Dwight Gorham, IntelGenx’s CEO.